GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-06-20| ChinaIPO

Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange

by Joy Lin
Share To

Shenzhen-based Joincare Pharmaceutical is said to be planning a secondary IPO listing on the SIX Swiss Stock Exchange, an unusual move for a Chinese biopharma. According to the pharma, a public debut in Switzerland could help “fund international financing channels, lift global image and branding, and meet the company’s need for global business development”.

While the exact fundraising size has not been disclosed, Joincare has picked state-owned investment company CITIC Securities to lead the offering, which could raise $300 to $400 million. 

 

IPO Listing in Switzerland Instead of the US

 

Pharmaceutical IPOs have stagnated over the past year as the world struggles with economic uncertainties such as the conflict in Ukraine. While most Chinese biopharmas have traditionally aimed for US IPOs, the US market has become increasingly restrictive. Both Chinese and US regulators have imposed tighter restrictions on companies listing in the US, with both sides raising concerns over data protection and auditing. 

Additionally, China last year expanded a stock connect scheme between Shanghai and London to include exchanges in Switzerland and Germany. The changes have prompted companies such as Sany Heavy Industry, Gotion High-Tech, Lepu Medical Technology to announce plans for a secondary listing on the Swiss Exchange. If Joincare jumps on the bandwagon, it could open a new path for Chinese biopharmas to list on the global stage. 

Related article: Belite Bio Clears Biopharma IPO Drought, with HilleVax and Tenon Medical Close Behind 

 

Profile of Joincare

 

Joincare is a pharmaceutical group with core businesses revolving around antibiotics (e.g. carbapenem and cephalosporins) and nutraceuticals. It owns two listed companies, Joincare and Livzon Pharmaceutical, more than 20 holding subsidiaries, and employs nearly 13,000 people. Currently, it has developed and deployed four “high-barrier complex preparation technology platforms”.

The company is developing a recombinant fusion protein vaccine booster against COVID-19 variants including Omicron, which is currently undergoing a global Phase 3 trial. 

In February, Joincare announced that its subsidiary Livzon has obtained NMPA approval to begin clinical trials on LZ001 for late-stage solid tumors. The drug, which comes in tablet form, is a ROS1/NTRK/ALK multi-target inhibitor designed to overcome drug resistance in solid tumors with the relevant mutations, mainly in non-small cell lung cancer.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
IPO
China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M
2025-01-24
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Biotech and Pharma IPOs Surge with Innovative Therapies in the Beginning of 2024: From Kymera Therapeutics to Kyverna Therapeutics Lead the Way
2024-01-18
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top